Observational Study on the Use of the Nutraceutical With Cardio-metabolic Actions in the Patient in Primary and Secondary Prevention
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Dyslipidemias
- Sponsor
- University of Pavia
- Enrollment
- 387
- Locations
- 1
- Primary Endpoint
- Prevalence of the use of nutraceutical in clinical practice
- Status
- Completed
- Last Updated
- 3 years ago
Overview
Brief Summary
The aim of this study will be to evaluate the use of the nutraceutical with cardio-metabolic actions in clinical practice in addition to a Mediterranean diet scheme, normally recommended in the clinic. In particular the study will analyze how much the nutraceutical is prescribed and what are the purposes for which it is used and at what dosages.
Detailed Description
The aim of this study will be to evaluate the use of the nutraceutical with cardio-metabolic actions in clinical practice in addition to a Mediterranean diet scheme, normally recommended in the clinic. In particular the study will analyze how much the nutraceutical is prescribed and what are the purposes for which it is used and at what dosages. In particular, attention will be focused on the following substances: berberine (500-1000 mg/day), monacolin (5-10 mg/day), phytosterols (0.9-1.8 g/day), resveratrol (100-500 mg/day), omega-3 (1-3 g/day), alpha lipoic acid (400-800 mg/day), curcumin (400 mg/day), psyllum (3.5 g/day), coenzyme Q10 (100-200 mg/day), inositol (250-600 mg/day), glucomannan (1-4 g/day), chitosan (800-1200 mg/day), guar fiber (10-20 g/day), L-arginine (250 mg/day).
Investigators
Giuseppe Derosa
Principal Investigator
University of Pavia
Eligibility Criteria
Inclusion Criteria
- •Diabetic patients in primary and secondary prevention or Hypertensive patients in primary and secondary prevention or Dyslipidemic patients in primary and secondary prevention
Exclusion Criteria
- •Patients with hystory of malignancy, and significant neurological or psychiatric disturbances, including alcohol or drug abuse.
Outcomes
Primary Outcomes
Prevalence of the use of nutraceutical in clinical practice
Time Frame: From 2010 to 2015
Prevalence